CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery by S. Ricciardi et al.
CDKL5 influences RNA splicing activity by its
association to the nuclear speckle
molecular machinery
Sara Ricciardi1,2, Charlotte Kilstrup-Nielsen1,3, Thierry Bienvenu4, Aure´lia Jacquette5, Nicoletta
Landsberger1,3 and Vania Broccoli1,2,
1Division of Neuroscience, San Raffaele Rett Research Center and 2Stem Cells and Neurogenesis Unit, Division of
Neuroscience, San Raffaele Scientific Institute, Milan 20132, Italy, 3Department of Structural and Functional Biology,
University of Insubria, Busto Arsizio, VA, Italy, 4Laboratoire de Ge´ne´tique et de Physiopathologie des Maladies Neuro-
de´veloppementales, Universite´ Paris Descartes, Institut Cochin, CNRS (UMR 8104), Inserm U567, 24 rue du
Faubourg Saint Jacques, Paris 75014, France and 5Service de Ge´ne´tique Me´dicale, AP-HP, Hoˆpital Pitie´-Salpe´trie`re,
47-83, Boulevard de l’Hoˆpital 75651, Paris Cedex 13, France
Received July 1, 2009; Revised and Accepted September 3, 2009
Mutations in the human X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been shown to cause
severe neurodevelopmental disorders including infantile spasms, encephalopathy, West-syndrome and an
early-onset variant of Rett syndrome. CDKL5 is a serine/threonine kinase whose involvement in Rett syn-
drome can be inferred by its ability to directly bind and mediate phosphorylation of MeCP2. However, it
remains to be elucidated how CDKL5 exerts its function. Here, we report that CDKL5 localizes to specific
nuclear foci referred to as nuclear speckles in both cell lines and tissues. These sub-nuclear structures
are traditionally considered as storage/modification sites of pre-mRNA splicing factors. Interestingly, we pro-
vide evidence that CDKL5 regulates the dynamic behaviour of nuclear speckles. Indeed, CDKL5 overexpres-
sion leads to nuclear speckle disassembly, and this event is strictly dependent on its kinase activity.
Conversely, its down-regulation affects nuclear speckle morphology leading to abnormally large and
uneven speckles. Similar results were obtained for primary adult fibroblasts isolated from CDKL5-mutated
patients. Altogether, these findings indicate that CDKL5 controls nuclear speckle morphology probably by
regulating the phosphorylation state of splicing regulatory proteins. Nuclear speckles are dynamic sites
that can continuously supply splicing factors to active transcription sites, where splicing occurs. Notably,
we proved that CDKL5 influences alternative splicing, at least as proved in heterologous minigene assays.
In conclusion, we provide evidence that CDKL5 is involved indirectly in pre-mRNA processing, by controlling
splicing factor dynamics. These findings identify a biological process whose disregulation might affect neur-
onal maturation and activity in CDKL5-related disorders.
INTRODUCTION
CDKL5 is an X-linked gene encoding a serine–threonine
kinase. It belongs to the cyclin-dependent kinase-like
(CDKL) family and shares partial homology with both MAP
and cell cycle-dependent kinases (1,2). The gene was orig-
inally found disrupted in a balanced X-autosomal translocation
in two unrelated female patients with a phenotype of severe
infantile spasms syndrome X-linked (3). Subsequently,
CDKL5 mutations have been found in more than 50 patients
exhibiting a large spectrum of neurological clinical manifes-
tations including early neonatal encephalopathy, drug resistant
infantile spasms, autism-like behaviour and severe mental
retardation (4–10). Furthermore, CDKL5 mutations are
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responsible for a specific form of Rett syndrome known as
Hanefeld or early-onset seizure variant where mutations in
MeCP2 are only rarely identified. From a clinical point
of view, the Hanefeld variant differs from the classic form
of Rett syndrome in the absence of an apparent period of
normal development while early-onset epileptic seizures are
evident soon after birth. Patients also display some of the clas-
sical symptoms of Rett syndrome, such as loss of speech,
stereotypic hand movements and microcephaly (11–14). Up
to now, a number of CDKL5 disease-causing mutations have
been identified; however, a general genotype–phenotype cor-
relation has not yet been established, leaving undetermined the
genetic bases of this variability (8–10). Rare cases of boys
with CDKL5 mutations or genomic deletions encompassing
the CDKL5 gene have been described exhibiting a severe clini-
cal phenotype with early-onset encephalopathy and intractable
epilepsy (15,16). From these recent reports, it appears evident
that CDKL5 pathogenetic mutations are a significant cause in
girls of severe early-onset neurodevelopmental disorders.
As mutations in MECP2 and CDKL5 are both associated
with Rett syndrome, their involvement in a common
pathway has been investigated. Interestingly, it has been
shown that the two proteins are widely co-expressed in the
brain and are similarly activated during neuronal maturation
and synaptogenesis (12,17). At the molecular level, the two
proteins interact together and CDKL5 mediates MeCP2 phos-
phorylation in vitro (12,18,19). However, it remains to be elu-
cidated which residues are phosphorylated by CDKL5 and
how MeCP2 activity is influenced by these modifications. Fur-
thermore, a recent report has suggested a new link between
CDKL5 and MeCP2. Both proteins have been shown,
indeed, to bind to DNA methyltransferase 1 an enzyme that
recognizes and methylates hemimethylated CpG dinucleotides
after DNA replication to maintain a correct methylation
pattern (19).
Despite this molecular correlation whose functional
meaning remains to be ascertained, there are reasons to
believe that CDKL5 also performs MeCP2-independent func-
tions. As a matter of fact, CDKL5 mutations are closely associ-
ated to some severe neurological symptoms, which are
occasionally reported in typical MeCP2 diseases, such as
infantile spasms, early-onset epilepsy and hypsarrhythmia.
Furthermore, while MeCP2 is a nuclear protein, CDKL5 shut-
tles between the cytoplasm and nucleus through a
CRM1-mediated nuclear export mechanism. Importantly, the
relative concentration of CDKL5 in each cellular compartment
varies in different brain areas and during development (17).
It has recently been demonstrated that a significant portion
of the endogenous CDKL5 localizes in the nuclear compart-
ment, where it displays a characteristic punctate staining.
This has been shown for a number of cell lines and neural
tissues (17,20). However, the exact identification of these
nuclear sub-compartments and their functions in the nuclear
processes has not yet been addressed.
Here, we report for the first time that CDKL5 localizes and
is associated with a number of splicing factors that are clus-
tered in structures called nuclear speckles. Moreover,
CDKL5 nuclear distribution is not affected by inhibition of
cellular transcription and is not mediated by the association
with RNA. Regarding the physiological role of CDKL5 in
nuclear speckles, we provide evidence that CDKL5, probably
through its ability to regulate the nuclear trafficking of splicing
factors, impairs the specificity of the splicing machinery. Our
data, thus, demonstrate a new role of CDKL5 in nuclear organ-
ization and might provide novel important insights regarding
the molecular mechanisms involved in Rett syndrome and
related neurodevelopmental disorders.
RESULTS
The nuclear fraction of CDKL5 is highly enriched
in the nuclear speckles
To investigate the subcellular localization of CDKL5, we per-
formed indirect immunofluorescence with a polyclonal
CDKL5 antibody. This has been previously prepared in our
laboratory, and its specificity has been confirmed in various
assays (17,20). In NIH3T3 cells as well as in HeLa cells,
endogenous CDKL5 exhibited a diffuse nucleoplasmic
pattern with an intense signal in organized granule-like sites
(Fig. 1A and data not shown). No signal was observed with
the pre-immune serum or when the incubation with the
primary antibody was omitted. Moreover, a similar pattern
of nuclear staining was also observed using an immuno-
purified serum. These findings indicate that the signal obtained
in our experimental conditions was highly specific. The pre-
viously identified interaction between CDKL5 and MeCP2,
suggested to us that the nuclear puncta of CDKL5 might cor-
respond to MeCP2 positive heterochromatic foci. However, in
Myc-MeCP2 transfected NIH3T3 cells, CDKL5 and MeCP2
did not co-localize, although rare double-positive puncta
were occasionally observed (Fig. 1A–C, arrowheads).
Accordingly, CDKL5-positive puncta did not localize with
the intensively Hoechst stained pericentric foci, which dis-
tinguish methylated CpG-rich DNA (Fig. 1D and F, arrows).
These results indicate that CDKL5 does not accumulate
within the heterochromatin domains, as MeCP2 normally
does. The staining pattern of CDKL5 was reminiscent of com-
partments enriched in RNA splicing and processing com-
ponents referred to as nuclear speckles. These are discrete
nuclear domains where pre-messenger RNA splicing factors,
ribonucleoprotein particles (snRNPs), spliceosome subunits
and non-snRNP protein splicing factors accumulate. Thus, it
is well accepted that nuclear speckles act as storage compart-
ments that can supply splicing factors to active transcription
sites (21–23). To determine whether CDKL5 might colocalize
with the nuclear speckles, we carried out immunofluorescence
experiments with antibodies against CDKL5 and some spli-
cing factors. SC35 is a non-snRNP splicing factor of the
serine-rich (SR) family of proteins, while Sm (Smith
antigen) associates with the snRNPs U1, U2, U4, U5 and U6
(21–23). Interestingly, the nuclear dots of CDKL5 were
found to overlap with SC35 staining and a similar
co-localization was obtained also with Sm (Fig. 1D–I). On
the other hand, CDKL5 was detected either in the nucleolus,
visualized by fibrillarin, staining or in the p80-coilin positive
Cajal bodies (data not shown). Thus, CDKL5 accumulates in
the splicing factor-rich nuclear speckles. The distribution of
CDKL5 in the nucleus as well as the co-localization of
CDKL5 with SC35 was also observed in 10 DIV primary
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mouse hippocampal neurons (Fig. 1J–L). To provide further
evidence that CDKL5 associates with the nuclear speckles,
we verified whether it could immunoprecipitate with the
nuclear speckles component SC35. To this end, NIH3T3
cells were transiently transfected with both YFP (control)
and YFP-SC35. The cells were recovered 16 h post-
transfection, and total cell extracts were subjected to
immunoprecipitation with a monoclonal anti-GFP antibody.
Immunoprecipitated proteins were then separated by SDS–
PAGE and visualized by immunoblotting with the polyclonal
CDKL5 antibody. As shown in Figure 1M, the endogenous
CDKL5 co-precipitated with YFP-SC35, but not with YFP.
Interestingly, CDKL5 exhibited a frank dot-like nuclear
pattern at least in some tissues, as scored, for instance, in
the principal CA1 neurons of the adult hippocampus (Sup-
plementary Material, Fig. S1). This finding indicates that the
spatial sub-nuclear compartmentalization of CDKL5 is also
observable in vivo.
Altogether, these data indicate that in the nucleus CDKL5
localizes to nuclear speckles and is found in a complex with
the SR protein SC35.
CDKL5 is an RNase-insensitive nuclear speckle component
Nuclear speckles are dynamic structures and act as storage/
assembly/modification compartments that can supply splicing
factors to active transcription sites. Their size, number and
shape can change depending on the transcription levels in
the cell and in response to environmental signals. The
effects of RNA polymerase-II (Pol-II) inhibitors on the
nuclear organization of splicing factors are well documented.
For example, in cells treated with 5,6-dichloro-1-beta-D-ribo-
benzimidazole (DRB), which specifically inhibits Pol-II,
nuclear speckles reduce in number, and concurrently enlarge
dramatically and acquire a more rounded-like appearance
(23). The same effects are seen with a-amanitin, another
Pol-II inhibitor (23). To explore the possibility that also
CDKL5-positive speckles might be modified by transcrip-
tional inhibitors, NIH3T3 cells and primary hippocampal
neurons were treated with DRB. Indeed, we observed a redis-
tribution of CDKL5 speckles into enlarged foci upon DRB
treatment, similar to that seen with SC35 or Sm (Fig. 2G–L;
compare with untreated cells in Fig. 2A–F). DRB treatment
of mouse primary hippocampal neurons produced a similar
outcome with the accumulation of large CDKL5/SC35
double positive nuclear speckles (Fig. 2M–R). Similar
results were obtained when transcription was halted using
the Pol-II inhibitor a-amanitin (data not shown).
It is well established that the structural stability of nuclear
speckles relies on two different types of protein interactions:
one that is resistant to RNase treatment (e.g. SC35) and
Figure 1. Nuclear CDKL5 accumulates into nuclear speckles. NIH3T3 cells
were transiently transfected with Myc-MeCP2. 24 h post-transfection, cells
were labelled for immunofluorescence with CDKL5 (B) and Myc antibodies
(A) to detect endogenous CDKL5 and recombinant Myc-tagged protein. In
(C), arrowhead point to a region of co-localization between CDKL5 and
MeCP2. (D and E) Immunostaining of CDKL5 and Hoechst, respectively.
(F) Merged image. In (D), arrowhead points to a CDKL5 nuclear foci.
Arrow in (E) indicates heterochromatic foci. To show co-localization with
speckle proteins, NIH3T3 cells and 10 DIV hippocampal neurons were
stained with CDKL5 antibody (G, J and M), and either monoclonal SC35
(H and N) or Sm antibodies (K). (I, L and O) Merged images. In (O),
arrows point the co-localization between CDKL5 and SC35 in hippocampal
neurons. (P) CDKL5 and SC35 interact in vitro. Total cell lysates of
NIH3T3 cells transfected with YFP (left panel) or YFP-SC35 (right panel)
was subjected to immunoprecipitation (IP) with monoclonal anti-GFP anti-
body. Immunoprecipitated proteins as well 10% of the cell extracts were sep-
arated by electrophoresis and analyzed by immunoblotting using antibodies
indicated on the left side of each panel. Scale bars: (A–I) 5 mm; (J–O) 10 mm.
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another that is RNase sensitive (e.g. snRNPs identified with
the Smith antigen-recognizing antibody Y12). To evaluate
the nature of the association of CDKL5 with the nuclear
speckles, NIH3T3 cells were permeabilized, fixed and then
treated with RNase (100 mg/ml, 2 h). The staining pattern of
CDKL5 resulted unaffected after RNA degradation, as
scored for SC35 immunoreactivity (compare Supplementary
Material, Fig. S2A, B with S2E, G). On the contrary, Sm stain-
ing became completely diffuse after RNase treatment
(compare Supplementary Material, Fig. S2D with S2H).
These results demonstrate that CDKL5 association to nuclear
speckles is not mediated through binding to RNA, but
depends on protein–protein interactions.
Overexpression of CDKL5 causes redistribution
of nuclear speckle components
It is well established that the dynamic association of SR proteins
to nuclear speckles is strictly dependent on their phosphoryl-
ation state. Indeed, it has been shown that phosphorylation of
the RS domain of SR splicing factors is necessary for their
release from speckles to sites where pre-mRNA splicing proces-
sing takes place. Several protein kinases have been described
that can phosphorylate the RS domain of SR proteins and the
two most extensively studied are SRPK1 and Clk/STY
(24,25). Transfection assays provide evidence that both
kinases, SRPK1 and Clk/STY, with the dual specificity to phos-
phorylate both Ser/Thr and Tyr residues, can target different
components of the nuclear speckles resulting in the complete
redistribution of splicing factors from speckles to a diffuse
nuclear pool (26–28). The above observations leave open the
possibility that also CDKL5, as a Ser/Thr protein kinase,
could have a role in nuclear speckle maintenance. To address
this question, NIH3T3 cells were transfected with a CDKL5
cDNA fused to GFP and 16 h post-transfection the nuclear
speckles morphology was analyzed by indirect immunofluores-
cence. Interestingly, in cells expressing GFP-CDKL5, we
observed a dramatic reduction of SC35 staining, which
remained confined to only small and fading foci (Fig. 3B and
D, arrowhead in B), whereas in neighbouring non-transfected
cells SC35 maintained its normal localization in the nuclear
speckles (Fig. 3B and C, arrow in C). To test whether this
effect of CDKL5 overexpression on speckles was general or
specific for SC35, we investigated the response of proteins
that localize to nuclear speckles but are not members of the
SR protein family. To this end, we stained cells for Sm, which
recognizes components of the snRNPs. Similar to that we
observed for SC35, in CDKL5 overexpressing cells, Sm posi-
Figure 2. CDKL5 nuclear distribution is not affected by inhibition of cellular transcription. NIH3T3 cells and 10 DIV hippocampal neurons were either left
untreated or treated with 100 mM 5,6-dicloro1-beta-D-ribobenzymidazole (DRB) in cell culture medium for 4 h at 378C. Cells were then labelled for immuno-
fluorescence with CDKL5 (A, D, G, J, M and P), SC35 (B, H, N and Q) and Sm (E and K) to detect endogenous proteins. (C, F, O, I, L and R) Merged images.
In both cellular types, speckles labelled with SC35 and Sm antibodies became larger, rounded-up and overlapped with CDKL5. Arrows in (I, L) and arrowheads
in (R) point to rounded-up nuclear speckles. (S and T) Quantification of the number of nuclear speckles for cells subjected to the indicated treatments. Quanti-
fication was performed visually by counting on the pictures the number of fluorescent foci in each cell. The values correspond to the means of three-independent
experiments (n ¼ 40 cells). Error bars represent standard deviations from the means. Scale bars: 5 mm.
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tive dots became dimmer and less distinct throughout the
nucleus (Fig. 3F–H, arrowhead in F). It is worthwhile to note
that the nuclear fraction of over-expressed CDKL5 was not
completely confined in dots but also distributed uniformly in
the nucleoplasm, as judged by the diffuse GFP signal, support-
ing the nuclear speckles disassembly hypothesis (Fig. 3A). At
this point, we asked whether the catalytic activity of CDKL5
was required for the effect of the kinase on nuclear speckle stab-
ility. Therefore, the kinase-dead mutant of CDKL5 (p.K42R),
which has previously been shown to be completely devoid of
phosphorylation activity, was overexpressed in NIH3T3 (20).
In contrast to the wild-type (WT) CDKL5, the catalytically inac-
tive mutant of CDKL5 was still noted in nuclear speckles and
failed to trigger any evident alteration in the SC35 staining
(Fig. 3I–L, arrow in L). These results suggest that CDKL5
does indeed cause disassembly of nuclear speckles in a kinase-
Figure 3. CDKL5 overexpression induces nuclear speckle components redistribution. NIH3T3 cells were transfected with either GFP-CDKL5 WT (A and E) or
GFP-CDKL5 K42R (I). Staining for GFP (A, E, I), SC35 (B, J), and Sm (F) was performed 16 h after cell transfections. NIH3T3 cells transfected with
GFP-CDKL5 WT show redistribution of both SC35 (B) and Sm (F) to a diffuse nuclear localization (arrowheads), in contrast to untransfected cells or cells
transfected with GFP-CDKL5 K42R in which SC35 is clearly localized in nuclear foci (C, G, K, L, arrows). (C, D, G, H, K and L) Enlargements of the
regions pointed by arrowheads. In (C, G and L), arrows point to a nuclear speckle. (M) NIH3T3 cells were left untransfected (lane 1) or were transfected
with GFP-CDKL5 WT (lane 2) or GFP-CDKL5 K42R (lane 3) and extracts analyzed by immunostainngs for GFP, Tubulin and Sm antibodies, showing no
differences in the levels of Sm. (N) Densitometric scanning quantification of the relative abundance of Sm in each fraction is presented in a bar graph.
Scale bars: 5 mm.
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dependent manner, resulting in a redistribution of at least some
speckle proteins. We reasoned that the reduction of SC35 and
Sm positive puncta might be the result of degradation of these
proteins or their redistribution throughout the nucleoplasm.
To address this issue, immunoblotting with Sm antibody was
performed on extracts of cells transfected with either
GFP-CDKL5 or GFP-CDKL5-K42R. In all three conditions,
the total amount of Sm protein was found not evidently
changed, suggesting that the loss of Sm positive puncta is
caused by a redistribution of the protein throughout the nucleo-
plasm. Together, these findings establish a role of CDKL5 in
regulating the dynamic behaviour of nuclear speckles.
CDKL5 disease-causing mutations affect nuclear
speckle structures
To further understand how CDKL5 exerts its function, we
wished to examine the effects on nuclear speckle organization
of different CDKL5 synthetic or disease-causing mutants.
Interestingly, the DN-CDKL5 mutant (p.M1_F297del),
lacking the entire kinase domain, did not affect nuclear
speckle disassembly similar to what was observed with the
K42R kinase-dead mutant (Fig. 4A–I). On the contrary, a
CDKL5 mutant lacking most of the C-terminal region
(D525), but preserving catalytic activity did induce the redis-
tribution of both SC35 and Sm, at a similar level to WT
CDKL5 (Fig. 4J–L and data not shown). These findings indi-
cate that CDKL5 kinase activity is necessary and sufficient for
regulating nuclear speckle homeostasis. Subsequently, we ana-
lyzed the effect on nuclear speckle disassembly, of a CDKL5
disease-causing missense mutations, p.R175S (c.525A.T),
that has been previously associated with encephalopathy and
early-onset variant of Rett syndrome (4). This mutation is par-
ticularly interesting since it has been previously described to
retain part of its autocatalytic activity and, therefore, to func-
tion as a hypomorphic mutant (17,18). Interestingly, overex-
pression in NIH3T3 cells of the p.R175S mutant induced a
loss of SC35 puncta, although the reduction was less dramatic
compared with CDKL5 WT (Fig. 4M–O). This indicates that
the p.R175S mutant, although exhibiting a reduced kinase
activity, is still able to notably affect nuclear speckle organiz-
ation when overexpressed. On the basis of the results obtained
for the kinase-defective mutants, it seems that the effect on
splicing factor redistribution is strictly dependent on CDKL5
kinase activity.
CDKL5 is necessary for proper coalescence of nuclear
speckle components
The results described above demonstrate for the first time that
CDKL5 is present in nuclear speckles and suggest a specific
function of the kinase in this sub-nuclear domain. Therefore,
to gain insights into this role, we analyzed the effect of the
absence of CDKL5 on nuclear speckle morphology, by
means of short-hairpin RNA (shRNA) mediated silencing
technology. To validate the CDKL5 shRNA, NIH3T3 cells
and hippocampal neurons were transfected with either
CDKL5 shRNA or, as control, a scrambled shRNA. The
cells were recovered 48 h post-transfection and the levels of
CDKL5 analyzed both by indirect immunofluorescence and
by immunoblotting (Supplementary Material, Fig. S3G). The
immunofluorescence experiments clearly showed that even if
CDKL5 was not completely depleted, its levels were signifi-
cantly reduced in CDKL5 shRNA treated cells compared
Figure 4. The catalytic domain of CDKL5 is required and sufficient for
nuclear speckles redistribution. NIH3T3 cells were transiently transfected
with each deletion mutants fused to GFP and then labelled for immunofluor-
escence with GFP (A, D, G, J and M) and SC35 (B, E, H, K and N) anti-
bodies. (C, F, I, L and O) Merged images. (A–C) Overexpression of the
CDKL5 wild-type (WT) form exerts a profound disassembly of the
SC35-positive nuclear speckles. (D–I) CDKL5 mutants K42R (D–F) and
DN (D1-297aa) (G–I) lacking the kinase activity do not exert any evident
changes in nuclear speckle distribution after exogenous expression. (J–L)
NIH3T3 cells overexpressing the D525 CDKL5 mutant form, which lack all
the C-terminal domain of the protein, exhibit a strong loss of SC35 immunor-
eactivity. (M–O) Forced expression of the pathogenic CDKL5 allele with a
missense mutation in the catalytic domain (R175S) is able to notably reduce
the number of SC35-positive nuclear puncta. The number of nuclear speckles
in transfected cells is represented in the chart (P). The values correspond to the
means of four-independent experiments (n ¼ 50 cells). Error bars represent
standard deviations from the means. Size bars: 5 mm.
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with control cells (Supplementary Material, Fig. S3C–F and
data not shown). A densitometric analysis of the immunoblot-
ting signals estimated that the levels of endogenous CDKL5
were reduced by 60% in CDKL5 shRNA treated cells
with respect to control cells (Supplementary Material,
Fig. S3H). Subsequently, we assessed whether CDKL5 knock-
down could trigger any alteration in nuclear speckle mor-
phology. Notably, the majority of CDKL5 silenced NIH3T3
cells presented larger and brighter nuclear speckles as high-
lighted by SC35 staining (Fig. 5D–F). Conversely, in cells
transfected with the scrambled shRNA (control shRNA),
SC35-positive nuclear speckles were not apparently affected
in their size (Fig. 5A–C). To investigate whether other com-
ponents of nuclear speckles were affected by interfering with
CDKL5, the localization of ASF/SF2 and Sm were investi-
gated. Overexpression of the SR family member ASF/SF2
fused to YFP permits to visualize nuclear speckles, where it
accumulates without affecting their activity (Fig. 5G) (23).
In contrast to untransfected cells or cells transfected with
scrambled shRNA (Fig. 5G–L, arrows in K), ASF/SF2-YFP
staining was detected in larger domains in cells interfered
for CDKL5 cells (Fig. 5G–L, arrows in K). Likewise, Sm
staining coalesced into larger nuclear domains in CDKL5
silenced, but not in control cells (Fig. 5M and N). The
above results clearly indicate that CDKL5 knockdown
induces an alteration of nuclear speckles morphology,
suggesting that endogenous CDKL5 is necessary for nuclear
speckle organization. To test whether the effect of CDKL5
knockdown was caused by a general gain in protein synthesis
or protein re-localization, we analyzed by immunoblotting the
expression levels of the endogenous ASF/SF2 protein. As in
the case of CDKL5 overexpression, the down-regulation of
the kinase did not lead to appreciable changes in the ASF/
SF2 protein levels. Indeed, in both CDKL5 silenced and
control cells ASF/SF2 protein levels were found unchanged
(Fig. 5O). Altogether, our results indicate that CDKL5 down-
regulation impacts nuclear speckle integrity.
CDKL5 mutant human primary skin fibroblasts show
abnormal morphology of nuclear speckles
Thus far, the presented results revealed an unsuspected role of
CDKL5 in the homeostasis of nuclear speckles. To analyze
whether pathogenic Rett (RTT)-causing mutations in CDKL5
influence this aspect, the above described experiments were
also conducted on primary cells of CDKL5-mutated patients.
The distribution of both the endogenous CDKL5 and SC35
was analyzed by indirect immunofluorescence in fibroblasts
of a girl carrying a premature stop codon (p.R59X) in the
CDKL5-coding region. This patient developed hypotonia and
pharmacological resistant myoclonic seizures within the first
year of life, followed by stereotypic hand movements
without noting regression (see Materials and Methods).
Control fibroblasts were obtained from two girls of 6 and 10
years old with a suspected myopathy, who resulted healthy
Figure 5. CDKL5 knockdown results in larger nuclear speckles. NIH3T3 cells
were transfected with control shRNA or CDKL5 shRNA. Cells were recovered
48 h post-transfection and labelled for immunofluorescence with GFP (A and
D) and SC35 antibodies (B and E). (C and F) Higher magnification of the
transfected cell nuclei. Arrows in (C) point to nuclear speckles. Arrows in
(F) point to rounded-up speckles. To show co-localization between ASF/SF2
and SC35, NIH3T3 cells were transfected with YFP-ASF/SF2 and stained
with GFP (G) and SC35 (H) antibodies. (I) Merged image. NIH3T3 cells
were transfected with YFP-ASF/SF2 alone (J) or in combination with
CDKL5 shRNA (K) or control shRNA (L), followed by immunostaining
with GFP antibody. Arrows in (K) point to rounded-up nuclear speckles.
Nuclear speckles were visualized by indirect immunofluorescence with Sm
antibody in NIH3T3 cells left untransfected (M) or transfected with CDKL5
shRNA (N). In (N), arrow indicates a rounded-up nuclear speckle. (O) Quanti-
fication of the number of nuclear speckles of cells treated with either shRNA
control or CDKL5 shRNA. Quantification was performed visually by counting
on the pictures the number of fluorescent foci in each cell. The values corre-
spond to the means of three-independent experiments (n ¼ 100 cells). Error
bars represent standard deviations from the means. (P) NIH3T3 cells were
left untransfected (lane 1) or were transfected with control shRNA (lane 2)
or CDKL5 shRNA (lane 3). Cells were recovered 48 h post-transfection and
the expression levels of endogenous ASF/SF2 were analyzed by immunoblot-
ting with ASF/SF2 antibody. (Q) Densitometric scanning quantification of the
relative abundance of ASF/SF2 in each fraction is presented in a bar graph.
Scale bars: (A, B, D, E) 10 mm; (G–N) 5 mm.
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after skin biopsy diagnostic examination. Interestingly, in
control human fibroblasts CDKL5 staining showed the same
features as observed both in NIH3T3 cells and in hippocampal
neurons. As inferred from Figure 6A–C, CDKL5-positive
nuclear foci resulted virtually coincident with the
SC35-positive nuclear domains. These data indicate that the
localization of CDKL5 in nuclear speckles is a conserved
feature of the protein in both mouse and human cells. Sub-
sequently, we analyzed nuclear speckle morphology in
CDKL5 mutant fibroblasts (p.R59X). These mutant fibroblasts
did not show any specific staining for CDKL5, indicating a
complete loss of functional protein. Simultaneously, CDKL5
mutant fibroblasts exhibited extremely large SC35-positive
nuclear domains. In particular, SC35 nuclear foci appeared
fewer, larger and less dot-like (Fig. 6D). Similar nuclear
speckle altered morphology was observed in fibroblasts iso-
lated from a second patient carrying a pathogenetic L220P
CDKL5 mutation (p.L220P) (Fig. 6E). Since CDKL5 mutation
is heterozygous, we scored both positive and negative CDKL5
cells within the same patient specific fibroblast cell population.
Interestingly, CDKL5-positive cells displayed a normal
content of SC35-positive nuclear speckles with a morphology
resembling that described in control fibroblasts (Fig. 6F).
Results obtained with NIH3T3 cells together with results
reported above consistently point to a key role of CDKL5 in
regulating nuclear speckle homeostasis. The finding that
CDKL5 down-regulation results in more round-up nuclear
speckles suggests that reduced phosphorylation of yet
unknown targets is most likely at the origin of this effect.
Specifically, we interpret these nuclear foci as nuclear speck-
les where splicing factors accumulate to a great extent leading
to a drastic increase of the speckle size.
To verify the effects of CDKL5 overexpression in patient
cells, we transfected CDKL5 human fibroblasts (p.R59X)
with GFP-CDKL5 and analyzed nuclear speckles morphology
as previous by visualizing SC35. Interestingly, mutant fibro-
blasts overexpressing GFP-CDKL5 showed a drastic loss of
SC35 staining, when compared with the non-transfected
cells (Fig. 6H–K). The ability of exogenous GFP-CDKL5 to
induce disassembly of nuclear speckles in fibroblasts devoid
of the kinase, confirms a crucial role of CDKL5 to regulate
the stability of these structures.
CDKL5 overexpression affects splicing
of a reporter minigene
Splice site selection and pre-mRNA splicing are dynamic pro-
cesses that involve constant remodelling of splicing factors,
such as SR proteins, on the pre-mRNA being processed. In
particular, alterations in the concentration of SR proteins in
areas where splicing occurs are thought to be critical for the
control of pre-mRNA splicing (29–31). It is by now well
established that phosphorylation events can modify the subcel-
lular localization of these regulatory proteins. This alters their
relative concentration at transcription sites, resulting in a
change in splice site selection. There are several pieces of evi-
dence that a number of kinases are able to phosphorylate SR
proteins (23,30). Furthermore, at least one of these, Clk/
STY, can modulate splicing in vitro (23). Therefore, it
would be conceivable that also CDKL5 might be involved in
pre-mRNA splicing. To address this question, we performed
an in vivo splicing assay using the Adenovirus E1A minigene.
In general, transfection of the adenovirus E1A construct into
cultured cells generates multiple RNA isoforms (9S, 12S
and 13S) due to the utilization of alternative 50 splice sites,
rendering it frequently employed as a reporter for alternative
Figure 6. Nuclear speckles morphology in patient-specific primary fibroblasts.
Human fibroblasts, CDKL5 R59X and CDKL5 L220P fibroblasts were immu-
nostained with CDKL5 (A) and SC35 (B, D, E and F) antibodies. (C) Merged
image. (G) Quantification of the number of nuclear speckles per cell. Quanti-
fication was performed visually by counting on the pictures the number of flu-
orescent foci in each cell. The values correspond to the means of
three-independent experiments (n ¼ 50 cells). Error bars represent standard
deviations from the means. CDKL5 R59X fibroblasts were transfected with
GFP-CDKL5 WT and then stained with GFP (H) and SC35 (I) antibodies.
Higher magnification of untransfected (J) and transfected cell nuclei (K) is
shown. Arrows in (J) show rounded-up nuclear speckles. Scale bars: (A–F)
5 mm; (H, I) 10 mm.
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splicing (Fig. 7A) (32–34). The E1A minigene was trans-
fected into NIH3T3 cells in combination with vectors expres-
sing GFP-CDKL5, GFP-CDKL5-K42R or GFP alone. The
presence of different splicing products was examined by semi-
quantitative RT–PCR. As shown in Figure 7B, CDKL5 over-
expression caused an increase of 9S and 12S isoforms and a
concomitant decrease of the 13S isoform together with the
unspliced pre-mRNA. Furthermore, we found that the
selection of the 9S 50 splice site selection is stimulated
by the catalytic activity of CDKL5 since the overexpression
of the kinase dead mutant (K42R) had no effect on the
splice site selection (Fig. 7B–E). These findings
illustrate the involvement of CDKL5 in the complex machin-
ery regulating pre-mRNA spliceosome activity and alternative
splicing.
DISCUSSION
The involvement of CDKL5 in the aetiology of several neuro-
developmental disorders, including early-onset encephalopa-
thy, infantile-spasms and atypical RTT, underscores the
importance of this protein in neuronal function. However, its
function is far from being entirely understood, precluding an
understanding of its role in the pathogenetic processes.
Herein, we describe a novel and unexpected role of CDKL5
in the structural organization of nuclear speckles and the
dynamics of their components. Surprisingly, CDKL5 ectopic
expression is sufficient to induce disassembly of the speckles
in both, cell lines and primary human fibroblasts. Conversely,
its down-regulation obtained by means of shRNA-mediated
silencing technology leads to consistent larger speckles.
Accordingly, CDKL5-mutated human primary fibroblasts
display abnormally large and uneven speckles. Together,
these results indicate that CDKL5 plays an important role in
the correct maintenance of speckle structures.
It is by now well known that a number of kinases act on
nuclear speckles morphology in a similar way as described
here for CDKL5. In fact, misexpression of different
members of the Clk/STY and SRPK kinase families lead to
a severe disassembly of nuclear speckles (24,25,27). Speckles
are thought to be the result of the aggregation of pre-mRNA
splicing factors, including ribonucleoprotein particles
(snRNPs) and arginine–serine-rich splicing factors. SR pro-
teins constitute a large family of highly evolutionary con-
served factors. These factors present a similar structure with
an N-terminal RNP type RNA binding domain and a C-
terminal region enriched in repeated arginine–serine dipep-
tides (RS domains) (26,27). Phosphorylation of serines
within the RS domains control their sub-nuclear localization
and binding to RNA. In fact, overexpression of SR-specific
Clk/STY and SRPK kinases elicit SR proteins to be released
from nuclear speckles and reach the active site of transcription
where they are assembled into the spliceosome (24,25,27).
Therefore, nuclear speckles should be considered highly
dynamic structures existing in equilibrium between continuing
assembly and disassembly of their protein components
(21–23).
Interestingly, the alterations of nuclear speckles caused by
CDKL5 misexpression appear mostly dependent by its
kinase activity as inferred from the results obtained upon
misexpression of different mutant derivatives. These results
Figure 7. CDKL5 affects E1A minigene splicing in vivo. (A) Schematic representation of the Adenovirus E1A minigene splicing pattern. Three splice isoforms
(13S, 12S and 9S) are produced by different 50 splice site selection. (B) NIH3T3 cells were left untransfected (lane 1) or were transfected with the E1A reporter
(lane 2) alone or in combination with GFP-CDKL5 WT (lane 3), GFP-CDKL5 K42R (lane 4) or GFP (lane 5). Total RNA was extracted and analyzed by RT–
PCR and 1.5% agarose gel electrophoresis. The positions of size standards are indicated on the right. (C–E) Quantitative analysis. The relative amounts of the
splice products (13S, 12S and 9S) were measured by densitometric scanning and the percentage of each isoform is expressed as the average with SEM (n ¼ 3).
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suggest that CDKL5 might exert a control on these sub-
nuclear structures by influencing the cycle of phosphorylation
and dephosphorylation of their associated SR proteins. Future
studies will be aimed to identify which of the numerous SR
proteins or, perhaps, other related nuclear speckle factors,
function as direct targets of CDKL5 mediating its effect on
speckles morphology.
We reported that CDKL5 misexpression influences alterna-
tive splicing of the Adenovirus E1A minigene, which in
general produces three major splice isoforms, depending on
different 50 splice sites (Fig. 7). It is well established that
alternative splicing is controlled by the type and amount of
SR proteins readily available at the sites of mRNA processing.
Indeed, the relative abundance of each single specific SR
protein and the molar ratio of each SR protein with respect
to their specific antagonists (e.g. hnRNP A/B family
members) determine the patterns of alternative splicing
(28,35–37). For example, increasing the concentration of
ASF/SF2 favours usage of the most downstream 50 splice
site in mRNAs containing alternative 50 splice sites (38). It
is, therefore, plausible, that the control of alternative splicing
mediated by CDKL5 is reached by influencing the delicate
equilibrium between the two pools of pre-mRNA splicing
factors associated to nuclear speckles or to the spliceosome.
Supporting this hypothesis, overexpression of the kinase-dead
CDKL5 mutant (K42R) was unable to elicit any alteration in
the splicing pattern of the E1A minigene, indicating that
downstream events of protein phosphorylation are necessary
for CDKL5 to regulate splicing activity.
Despite the fact that CDKL5 has been shown to work in a
pathway common with that of MeCP2 (12), there are
reasons to believe that CDKL5 also performs
MeCP2-independent functions. In this work, we describe a
specific function played by CDKL5 in regulating nuclear
speckle homeostasis, which has never been associated with
MeCP2. Indeed, unlike MeCP2, CDKL5 is closely associated
with and can alter the morphology of these nuclear structures.
Thus, herein, we described the first MeCP2-independent
CDKL5 function in this specific biological complex. We
hypothesize that any CDKL5 dysfunction in this process
results in an imbalance of the various components of the
spliceosome machinery, which ultimately leads to alterations
of the splicing pattern of a number of undefined RNA
transcripts.
Therefore, CDKL5 dysfunction might cause a general
alteration in RNA processing and splicing regulation, which
could be particularly deleterious for the maturation, function
or survival of brain neurons. To our knowledge, CDKL5 is
the first non-snRNP associated nuclear speckle protein
mutations in which are responsible for neurological disorders.
In fact, whereas mutations causing retinal degeneration have
been described in the genes PRPF31, PRPF8 and PRPF3
coding for proteins of the snRNPs complexes (39), no
mutations in other components of the nuclear speckle
structures have yet been found responsible for other human
genetic disorders. Aberrant RNA processing associated with
both neuronal cell death and neurological symptoms have
been described in individuals with mutations in the SMN1 or
TARDBP (TDP43, ALS10) genes, causing spinal muscular
atrophy and amyothrophic lateral sclerosis, respectively (40).
Both SMN1 and TARDBP encode hnRNP-associated proteins
with a presumptive role in controlling splicing pattern activity
(41,42). Interestingly, in SMN1-deficient mice, aberrant
alternative splicing was observed in various tissues and for
numerous genes, even though this global alteration is
coupled with the only specific degeneration of motor spinal
neurons (43). However, RTT is distinct with respect to these
pathologies, since it has been reported to lack a clear associ-
ation with its pathological course and any notable neuronal
cell death process (44).
Intriguingly, MeCP2 itself has been also involved in regu-
lating alternative splicing. Indeed, MeCP2 is able to regulate
splicing of reporter minigenes, probably trough its direct inter-
action with the RNA-associated protein YB1 (45). Most
importantly, MeCP2 mutant animals displayed aberrant spli-
cing for a number of target genes expressed predominantly
in the brain (45). Thus, both CDKL5 and MeCP2 have roles
in RNA processing regulation although with apparently differ-
ent molecular mechanisms. However, it might be possible that
direct links exist between CDKL5 and MeCP2 dependent
regulation of RNA processing. Considering these result, it
might be proposed that classical, early-onset RTT and
similar CDKL5-dependent neurodevelopmental disorders
might be the results of an aberrant RNA metabolism particu-
larly deleterious for neuronal function.
Future experiments, including development of in vivo
model systems, will be essential in sorting out the impact of
the CDKL5-regulated mechanisms impinging on RNA proces-
sing during neuronal maturation and activity.
MATERIAL AND METHODS
Patient ascertainment
Patient with the R59X-mutated CDKL5 was the third child of
healthy, unrelated parents. The first children were normal. She
was born at term after an uneventful pregnancy. Her birth
weight was 2720 g, height 46 cm and head circumference
32 cm. During the first weeks of life, the mother noted poor
visual contact. When she was 2 months old, she was referred
to a paediatric hospital for an acute gastroenteritis. At that
time, hypotonia and seizures were noted. She had head
control at 9 months, sat at 3 years but did not achieve indepen-
dent walking. Hand use was limited to gross manipulation and
she was unable to transfer objects from one hand to the other.
She had no speech. She developed generalized tonic–clonic
and myoclonic epilepsia. Seizures were brief, lasting
,1 min but frequent (2 or 3 per day) and refractory to medi-
cation. EEG showed paroxysmal activity with generalized
spikes on a low background rhythm. She had midline stereoty-
pic hand movements and auto aggressive behaviour (biting)
but no regression. She had an early and severe gastro oesopha-
geal reflux and was predominantly fed by a gastrostomy tube.
A severe scoliosis was treated surgically at the age of 14 years.
Physical examination at the age of 17 years showed poor eye
contact and poor eye fixation, strabismus, nystagmus and
spastic paraparesis. The height and head circumference were
on 2.5 SD, the weight on 4 SD. Additional features included
very small feet and hands and some dysmorphic features:
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wide nasal bridge, broad nasal tip, down slanting palpebral fis-
sures and malar hypoplasia.
Cell culture and transfection
NIH3T3 cells, HeLa cells, human fibroblasts were maintained
in Dulbecco’s modified Eagle’s medium (Invitrogen, Eugene,
OR, USA) supplemented with 1% penicillin–streptomycin
(Sigma-Aldrich, St Louis, MO, USA), 2 mM glutamine
(Sigma-Aldrich) and 10% fetal bovine serum (Invitrogen) at
378C with 5% CO2. Transient DNA transfections were
carried out using calcium phosphate precipitation method or
Lipofectamine Plus Reagent (Invitrogen), according to manu-
facturer’s instructions and cells harvested 16–48 h post-
transfection. Cells were treated with DRB at 100 mM for 4 h
and with a-amanitin at 50 mg/ml for 5 h.
Primary hippocampal cultures
Primary neuronal cultures were prepared from the hippo-
campus of day 17.5 mouse embryos (E17.5). Briefly, hippo-
campi were dissected from mouse brains under a dissection
microscope and treated with trypsin (Invitrogen) for 15 min
at 378C before triturating mechanically with fire-polished
glass pipette to obtain a single-cell suspension. Approximately
7  104 cells were plated on coverslips coated with
poly-L-lysine in 12-well plates and cultured in Neurobasal
medium (Invitrogen) supplemented with B27 (Invitrogen)
and glutamine (Sigma-Aldrich). Neurons were fixed for immu-
nostaining at 10 days after plating.
Plasmids and RNAi
pGFP-hCDKL5, pGFP-K42R, pGFP-DN, pGFP-D525,
pGFP-C152F and pGFP-R175S were described previously
(20). pE1A was a kind gift of D. Gabellini, pYFP-SC35 and
pYFP-ASF/SF2 was kindly provided by D. Spector.
RNAi was performed using shRNAs expressed by
pU6-mir30 vector. To generate shRNA-expressing plasmids,
we have designed three different target sequences for the
target CDKL5 gene and a mismatch sequence, which have
subsequently been inserted into pU6-mir30 vector at EcoRI
and XhoI restriction sites. The so prepared constructs were
verified by DNA sequencing. The following targeted
sequences were designed: CDKL5 shRNA no. 1 (CATTGG
TAATGTGATGAATAAA), CDKL5 shRNA no. 2 (GGG
ACATTATTTCCCTGCTTAC), CDKL5 shRNA no. 3
(AACACTGACGGTCCTGATCTAT). For CDKL5 shRNA
validation, NIH3T3 cells were plated in six-well plates and
transfected with 3 mg of shRNA plasmid and 1 mg of an
appropriate reporter gene, using Lipofectamine Plus Reagent
(Invitrogen), according to manufacturer’s instructions. The
reporter used was: pCAGGS-GFP. Cells were monitored for
48 h following transfection and the expression levels of
endogenous CDKL5 analyzed by immunofluorescence and
immunoblotting. Among the three shRNA-expressing
plasmid, the one containing the target sequence no. 1,
CATTGGTAATGTGATGAATAAA, was chosen for the
study.
Immunofluorescence
Cells growing on coverslips in 12-well plates were left untreated
or were transfected with different expression constructs. At 16 or
48 h after transfection, cells were washed in phosphate-buffered
saline (PBS) and fixed for 5 min in methanol (2208C). Cells
were rehydrated in PBS and incubated with primary antibodies
diluted in 0.5% goat serum (Sigma) in PBS for 16 h at 48C.
Cells were rinsed in PBS, then secondary antibodies were
added for 1 h at room temperature. The following antibodies
were used: immunopurified rabbit polyclonal anti-CDKL5
(1:5) (17), mouse monoclonal anti-SC35 (1:20, Sigma-Aldrich),
mouse monoclonal anti-Sm (1:100, Thermo Scientific, Fremont,
USA), mouse monoclonal anti-GFP (1:500, Invitrogen), rabbit
polyclonal anti-GFP (1:500, Invitrogen). Alexa 488 and 594
anti-mouse and anti-rabbit IgG secondary antibodies (1:500,
Molecular Probes) were used for detection. Coverslips were
mounted onto slides in fluorescent mounting medium (DakoCy-
tomation, Glostrup, Denmark) and analyzed with a Nikon
Eclipse E600 fluorescent microscope (Nikon, Tokyo, Japan).
Images were captured using a digital camera (DXM 1200,
Nikon) with the ACT-1 software (Nikon).
Western blotting
NIH3T3 cells were plated in six-well plates, transfected with
Lipofectamine Plus Reagent and harvested in ice-cold PBS.
Cells were lysed in lysis buffer (Tris–HCl 50 mM pH 8.0,
NaCl 150 mM, 1% NP-40, 0.1% SDS and a mix of phosphatases
and proteases inhibitors from Sigma-Aldrich) for 15 min at 48C.
Lysates were clarified by centrifugation for 15 min at 18 000g,
and protein concentration of the supernatant was determined
using BSA as a standard (Bradford reagent assay,
Sigma-Aldrich). Total lysates were boiled in SDS sample
buffer, separated by SDS–PAGE and blotted to nitrocellulose
membrane (Amersham). Filters were blocked in tris-buffered
saline tween-20 (0.1%) (TBST) (10 mM Tris–HCl, pH 8.0,
150 mM NaCl and 0.05% Tween-20) plus 5% dried milk and
incubated with primary antibodies for 16 h at 48C. The following
primary antibodies were used: rabbit polyclonal anti-CDKL5
(1:100), mouse monoclonal anti-ASF/SF2 (1:500), mouse mono-
clonal anti-Sm (1:100, Thermo Scientific), mouse monoclonal
anti-Tubulin (1:1000, Sigma-Aldrich), mouse monoclonal
anti-GFP (1:500, Roche Diagnostics, Basel, Switzerland),
rabbit polyclonal anti-GFP (1:250, Invitrogen). After washing
three times with TBST, filters were incubated with peroxidase-
conjugated secondary antibodies (anti-mouse or rabbit Ig;
1:5000) (Amersham) for 1 h at room temperature. Detection
was performed by enhanced chemiluminescence (EuroClone,
Pero, Italy). For quantitative measurements, autoradiographs
were scanned and signal intensity assessed with ImageJ (NIH)
software.
Immunoprecipitation
For co-immunoprecipitation, NIH3T3 cells were grown on
100 mm Petri dishes and transiently transfected with calcium
phosphate precipitation method. At 24 h after transfection,
cells were collected, resuspended in lysis buffer (Tris–HCl
50 mM pH 8.0, NaCl 150 mM, 1% NP-40) supplemented with
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protease and phophatase inhibitors (Sigma-Aldrich), and cen-
trifuged for 15 min at 18 000g at 48C. The extract was immu-
noprecipitated with 10 ml of anti-GFP monoclonal antibody
(Roche-Diagnostics) for 16 h at 48C; 50 ml of Protein
G-agarose beads (Invitrogen) were then added and the immu-
noprecipitate was further incubated for 4 h at 48C. Immuno-
complexes were collected by centrifugation, washed three
times with lysis buffer, separated on a 8% SDS–PAGE,
blotted to nitrocellulose membrane (Amersham) and analyzed
by western blot.
E1A splicing assay
NIH3T3 cells grown on six-well plates were co-transfected
with 1 mg of E1A plasmid and 4 mg of either
GFP-CDKL5-WT, GFP-CDKL5-K42R or GFP empty
vector. At 24 h after transfection, cells were harvested and
total RNA was with RNAeasy Micro Kit (Quiagen). Reverse
transcription was carried out on 2 mg of total RNA, using
oligo-dT and with Transcriptor High Fidelity cDNA Synthesis
Kit (Roche). The E1A splice isoforms were detected by PCR
using E1A primers (50-TTTGGACCAGCTGATCGAAG-30
and 50-TAACCATTATAAGCTGCAAT-30). Amplification
was carried out for 23 cycles in a 25 ml volume with 2 ml
of cDNA. PCR products were resolved on 1.5% agarose gel,
visualized by ethidium bromide staining and quantitated by
densitometric scanning.
Human primary skin fibroblasts
After informed consent from the parents, a skin biopsy was
performed from the upper arm of the girl carrying the
p.R59X CDKL5 mutation. A primary dermal fibroblast
culture was concomitantly established. Fibroblasts were cul-
tured in Dulbecco’s modified Eagle’s medium with gluta-
MAX, supplemented with 10% fetal calf serum (Gibco,
Invitrogen, Cergy-Pontoise, France), penicillin (100 IU/ml)
and streptomycin (100 mg/ml) (PAA Laboratories, Pasching,
Austria) in a humidified atmosphere containing 5% CO2 at
378C. Passages two to five were used for the experiments.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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